Press release
NSCLC Clinical Trials Assessment 2025: Therapeutics Landscape, FDA Approvals, Pipeline Analysis, Competitive Landscape, Therapies, Medication, ROA, MOA by DelveInsight
NSCLC Clinical Trials Assessment
Non-Small Cell Lung Cancer Clinical Trial Summary
The NSCLC pipeline is highly active, with 135+ companies developing 150+ therapies. Key players include Daiichi Sankyo, Merck, Pfizer/AbbVie, Eli Lilly, BioNTech, Bristol Myers Squibb, Bayer, and Innovent Biologics. Promising candidates include trastuzumab deruxtecan, DS-1062a, pembrolizumab, domvanalimab, zimberelimab, cemiplimab, osimertinib, and others. Recent updates highlight FDA designations and trial progress: Boan Biotechnology's BA1302 received ODD (March 2025); CERo gained IND clearance for CER-1236 (March 2025); Dizal's Sunvozertinib received priority review (Jan 2025); and Nuvation Bio's taletrectinib NDA was accepted (Dec 2024). Major studies by Merck, AstraZeneca, and Gilead are advancing combination therapies to improve outcomes in early and metastatic NSCLC.
DelveInsight's, "Non-Small-Cell Lung Cancer Pipeline Insight 2025" report provides comprehensive insights about 135+ NSCLC Companies and 150+ pipeline drugs in the Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay Ahead in the NSCLC Landscape - Explore detailed profiles of 135+ companies, 150+ pipeline therapies, trial updates, and emerging treatment strategies. Access the full NSCLC Clinical Trial Report [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Key Takeaways from the NSCLC Pipeline Report
* DelveInsight's NSCLC pipeline report depicts a robust space with 135+ active players working to develop 150+ pipeline therapies for NSCLC treatment.
* The leading NSCLC Companies working in the market include BridgeBio Pharma, Daiichi Sankyo, EMD Serono/Merck, BridgeBio Pharma, Abbvie/Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, and others.
* Promising NSCLC Pipeline Therapies in the various stages of development include Trastuzumab deruxtecan, DS-1062a, Docetaxel, Pembrolizumab (MK-3475) 200 mg, Domvanalimab, Zimberelimab, Quemliclustat, BNT116, Cemiplimab, SKB264, Carboplatin, Osimertinib, and others.
* In March 2025, Boan Biotechnology (06955.HK) announced that its CD228-targeting antibody-drug conjugate, BA1302, had been granted orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of squamous non-small cell lung cancer and pancreatic cancer.
* In March 2025, CERo Therapeutics Holdings, Inc. reported that the FDA had cleared its second Investigational New Drug (IND) application for its lead candidate, CER-1236, enabling the company to initiate a Phase 1 clinical trial in patients with advanced solid tumors, including non-small cell lung cancer and ovarian cancer.
* In January 2025, the FDA granted priority review to Dizal's new drug application (NDA) for Sunvozertinib, intended for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
* In December 2024, Nuvation Bio Inc., a global oncology-focused biopharmaceutical company, announced that the FDA had accepted its NDA submission for taletrectinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) being developed for the treatment of advanced ROS1-positive NSCLC, regardless of prior treatment history.
* December 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for V940 and Pembrolizumab. The goal of this study is to evaluate V940 plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of completely resected (R0) Stage II, IIIA, IIIB (with nodal involvement [N2]) NSCLC. The primary hypothesis is that V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator.
* December 2023: AstraZeneca announced a study of Phase 2 clinical trials for Durvalumab, Oleclumab, Monalizumab, MEDI5752, and AZD0171. The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab or AZD0171 and platinum doublet chemotherapy; or MEDI5752 in combination with platinum doublet chemotherapy or datopotamab deruxtecan (Dato-DXd) in combination with durvalumab and single agent platinum chemotherapy in participants with resectable, early-stage NSCLC.
* December 2023: Gilead Sciences announced a study of Phase 3 clinical trials for Zimberelimab, Domvanalimab, Pembrolizumab, Carboplatin, and Cisplatin. The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on progression-free survival (PFS) and overall survival (OS) in patients with untreated metastatic NSCLC with no actionable genomic alteration.
Request a sample and discover the recent advances in NSCLC Treatment Drugs @ NSCLC Pipeline Outlook Report [https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
NSCLC Overview
NSCLC (Non-Small Cell Lung Cancer) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases globally. NSCLC typically grows and spreads more slowly than small cell lung cancer, offering a broader window for treatment interventions. NSCLC symptoms often include persistent coughing, chest pain, shortness of breath, and unexplained weight loss. NSCLC diagnosis usually involves imaging tests such as CT scans, biopsies, and molecular profiling to determine genetic mutations. NSCLC staging ranges from localized Stage I to advanced metastatic Stage IV, significantly impacting treatment decisions.
NSCLC treatment options include surgery, radiation therapy, chemotherapy, targeted therapies, and emerging immunotherapies. NSCLC targeted therapies focus on specific mutations like EGFR, ALK, and ROS1, offering personalized treatment approaches. NSCLC immunotherapy has transformed patient outcomes by harnessing the body's immune system to fight cancer cells. NSCLC clinical trials continue to explore innovative drugs and combination therapies to improve survival rates.
NSCLC prognosis varies based on stage, patient health, and genetic factors, with early detection being crucial for better outcomes. NSCLC research and development are rapidly evolving, bringing hope for more effective therapies. As awareness and advanced treatments grow, the NSCLC landscape continues to change, improving patient care worldwide.
Find out more about NSCLC Treatment Landscape @ Drugs for NSCLC Treatment [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
NSCLC Emerging Drugs Profile
V940 (Merck Sharp & Dohme LLC) V940 is an mRNA-based personalized cancer vaccine designed to trigger T-cell responses using up to 34 neoantigens derived from a patient's tumor mutations. It is currently in Phase III trials for NSCLC.
QL1706 (Qilu Pharmaceutical Co., Ltd.) QL1706 is a bifunctional antibody combining PD-1 and CTLA-4 blockade to enhance anti-tumor activity. It is in Phase III development for NSCLC.
Zenocutuzumab (MCLA-128; Merus N.V.) Zeno is a bispecific antibody that blocks HER3/NRG1 fusion signaling by binding HER2 and preventing HER2-HER3 interaction, thereby inhibiting tumor growth. It is in Phase II for NSCLC.
ZW49 (Zymeworks BC Inc.) ZW49 (zanidatamab zovodotin) is a bispecific HER2-targeted antibody-drug conjugate based on ZW25, delivering a cytotoxic payload while blocking HER2 signaling. It is in Phase I trials for NSCLC.
NSCLC Pipeline Therapeutics Assessment
There are approx. 135+ key NSCLC companies which are developing the NSCLC therapies. The NSCLC companies which have their Non-Small-Cell Lung cancer (NSCLC) drug candidates in the most advanced stage, i.e. Phase III include Daiichi Sankyo.
DelveInsight's NSCLC Pipeline report covers around 150+ products under different phases of clinical development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Non-Small-Cell Lung cancer ROA
Non-Small-Cell Lung cancer Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Subcutaneous
* Intravenous
* Oral
* Parenteral
* Intramuscular
NSCLC Products have been categorized under various Molecule types such as
* Small molecules
* Peptides
* Polymer
* Gene Therapy
* Monoclonal antibodies
Learn more about the emerging NSCLC Pipeline Therapies @ NSCLC Clinical Trials Assessment [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Non-Small Cell Lung Cancer Market Drivers
* High Disease Burden: NSCLC accounts for ~85% of all lung cancers, ensuring strong demand for therapies.
* Advances in Targeted Therapies: Growth driven by EGFR, ALK, ROS1, KRAS, and PD-1/PD-L1 inhibitors, expanding precision medicine options.
* Immunotherapy Expansion: Drugs like pembrolizumab, cemiplimab, and durvalumab have revolutionized treatment with survival benefits.
* Strong R&D Pipeline: 150+ therapies in development with innovative mechanisms (FcRn inhibitors, antibody-drug conjugates, next-gen TKIs).
* Regulatory Support: Multiple FDA designations (priority reviews, orphan drug, breakthrough therapy) accelerate drug development.
* Growing Diagnostic Advancements: Improved biomarker testing (PD-L1, NGS panels) supports early detection and patient stratification.
Non-Small Cell Lung Cancer Market Barriers
* High Treatment Costs: Targeted therapies and immunotherapies impose significant financial burden on patients and healthcare systems.
* Drug Resistance: Many patients develop resistance to EGFR, ALK, and KRAS inhibitors, limiting long-term efficacy.
* Heterogeneity of NSCLC: Genetic and molecular diversity complicates treatment personalization.
* Access and Affordability Gaps: Limited access to advanced therapies in low- and middle-income countries restricts global adoption.
* Adverse Effects: Immunotherapy-related toxicities and long-term safety concerns affect compliance and quality of life.
* Clinical Trial Challenges: Complex trial designs, recruitment issues, and stringent regulatory hurdles slow development timelines.
Scope of the Non-Small Cell Lung Cancer Pipeline Report
* Coverage- Global
* NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* NSCLC Companies- BridgeBio Pharma (NASDAQ: BBIO), Daiichi Sankyo (TYO: 4568), EMD Serono/Merck (FWB: MRK), AbbVie (NYSE: ABBV)/Pfizer (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), BioNTech SE (NASDAQ: BNTX), Shenzhen TargetRx (Private), Taiho Pharmaceutical (Private), Chong Kun Dang (KRX: 185750), Bristol Myers Squibb (NYSE: BMY), Innovent Biologics (HKEX: 01801), Xuanzhu Biopharmaceutical (Private), Bayer (FWB: BAYN), GeneScience Pharmaceuticals (Private), InventisBio (SHA: 688382), Apollomics (NASDAQ: APLM), Imugene (ASX: IMU), Ono Pharmaceutical (TYO: 4528)/Pierre Fabre (Private), Jiangsu Hengrui Medicine Co. (SHA: 600276), Surface Oncology (acquired by Coherus BioSciences, NASDAQ: CHRS), Inhibrx (NASDAQ: INBX), Sinocelltech (SHA: 688520), Mirati Therapeutics (NASDAQ: MRTX), REVOLUTION Medicines (NASDAQ: RVMD), Yong Shun Technology Development (Private), Iovance Biotherapeutics (NASDAQ: IOVA), Galecto Biotech (NASDAQ: GLTO), and others.
* NSCLC Pipeline Therapies in the various stages of development include Trastuzumab deruxtecan, DS-1062a, Docetaxel, Pembrolizumab (MK-3475) 200 mg, Domvanalimab, Zimberelimab, Quemliclustat, BNT116, Cemiplimab, SKB264, Carboplatin, Osimertinib, and others.
Dive deep into rich insights for new drugs for NSCLC treatment, Visit @ NSCLC Market Drivers and Barriers, and Future Perspective [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Content
Introduction
Executive Summary
Non-Small-Cell Lung cancer (NSCLC) : Overview
* Introduction
* Causes
* Pathophysiology
* Signs and Symptoms
* Diagnosis
* Treatment
Pipeline Therapeutics
* Comparative Analysis
Therapeutic Assessment
* Assessment by Product Type
* Assessment by Stage and Product Type
* Assessment by Route of Administration
* Assessment by Stage and Route of Administration
* Assessment by Molecule Type
* Assessment by Stage and Molecule Type
Non-Small-Cell Lung cancer (NSCLC) - DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
* Comparative Analysis
V940: Merck Sharp & Dohme LLC
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report.....
Mid Stage Products (Phase II)
* Comparative Analysis
Zenocutuzumab (MCLA-128): Merus N.V.
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report.....
Early Stage Products (Phase I)
* Comparative Analysis
ZW49: Zymeworks BC Inc.
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report.....
Preclinical and Discovery Stage Products
* Comparative Analysis
Drug name: Company name
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
* Comparative Analysis
Non-Small-Cell Lung cancer (NSCLC) Key Companies
Non-Small-Cell Lung cancer (NSCLC) Key Products
Non-Small-Cell Lung cancer (NSCLC) - Unmet Needs
Non-Small-Cell Lung cancer (NSCLC) - Market Drivers and Barriers
Non-Small-Cell Lung cancer (NSCLC) - Future Perspectives and Conclusion
Non-Small-Cell Lung cancer (NSCLC) Analyst Views
Non-Small-Cell Lung cancer (NSCLC) Key Companies
Appendix
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nsclc-clinical-trials-assessment-2025-therapeutics-landscape-fda-approvals-pipeline-analysis-competitive-landscape-therapies-medication-roa-moa-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release NSCLC Clinical Trials Assessment 2025: Therapeutics Landscape, FDA Approvals, Pipeline Analysis, Competitive Landscape, Therapies, Medication, ROA, MOA by DelveInsight here
News-ID: 4167147 • Views: …
More Releases from ABNewswire
GAINSWave Therapy for Arthritis and Joint Health Applications
GAINSWave Registered , a nationwide leader in regenerative therapy, is expanding its low-intensity shockwave protocols to treat arthritis and joint-related conditions. This non-invasive, drug-free approach promotes natural tissue regeneration and improved blood flow, offering patients a highly sought-after alternative to surgery, stem cells, and long-term medication for joint pain and mobility issues. The brand has also launched new clinical training and guidelines for providers nationwide.
AVENTURA, FL - GAINSWave Registered ,…
Triple Negative Breast Cancer Market Positioned for Accelerated Development Thro …
The Key Triple Negative Breast Cancer Companies in the market include - Sichuan Kelun-Biotech Biopharmaceutical, Akeso Biopharma, ProLynx, ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs, Abbisko Therapeutics, BioLite, Inc., Zenith Epigenetics, HiberCell, Inc., Infinity Pharmaceuticals, G1 Therapeutics, Inc, Jiangsu HengRui Medicine Co., Ltd, Shanghai Henlius Biotech, and others.
DelveInsight's "Triple Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Triple Negative Breast Cancer, historical…
ProStar SEO Releases Insights on How Businesses Can Select the Best SEO Agency i …
Image: https://www.abnewswire.com/upload/2025/12/2d87888ac23829a685ed0aac8668f013.jpg
Semantic SEO Is the Definitive Selection Criterion for Toronto Businesses
Semantic SEO is the fundamental competency that distinguishes profitable agencies from obsolete practitioners. Toronto businesses that partner with semantic-focused agencies achieve measurably higher organic conversion rates than those using only keyword-density approaches. Google's algorithm evolution demonstrates that agencies must prioritize addressing user intent and providing contextual relevance over focusing on traditional keyword density. Statistical analysis confirms semantic optimization generates significantly…
New Jersey Real Estate Attorney Christine Matus Highlights the Importance of Hom …
TOMS RIVER, NJ - Buying a home is a major milestone and financial commitment, and Christine Matus, a seasoned New Jersey real estate attorney at The Matus Law Group (https://matuslaw.com/do-you-need-a-home-inspector-when-buying-a-house-in-new-jersey), emphasizes the importance of conducting a home inspection before completing a property purchase. While not required by law, a home inspection is one of the most practical steps buyers can take to safeguard their investment and protect themselves from costly…
More Releases for NSCLC
NSCLC Patient Insights You Can't Afford to Ignore! A DelveInsight Case Study - H …
DelveInsight, a global leader in healthcare market intelligence and consulting, has successfully partnered with a top-tier biopharmaceutical company specializing in oncology to provide an advanced epidemiology forecasting analysis of Non-Small Cell Lung Cancer (NSCLC). This comprehensive study focused on biomarker-specific segmentation to support strategic drug development, identify target patient populations, and optimize market access planning across global markets.
With the increasing complexity of NSCLC treatment, biomarker-driven therapies have emerged as a…
Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC
Pemetrexed disodium is a drug successfully developed by Eli Lilly in the United States for the treatment of tumors, patent protection to January 2017. Pemetrexed disodium is a multi-targeted anti-folate agent with a core pyrrolopyrimidine moiety in its structure. It is a dual inhibitor of nucleotide synthase/dihydrofolate reductase, which inhibits cell replication by disrupting the normal process of folate-dependent metabolism in cells and simultaneously blocking three different enzyme targets critical…
NSCLC Market Global Industry Analysis and Forecast Till 2027
Any type of epithelial lung cancer that isn't small cell lung cancer is referred to as NSCLC (SCLC). Squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the most common kinds of NSCLC, although there are several more types that are less common, and all types can occur in atypical histologic variants.
Request Sample Copy of this Report: https://www.infinitybusinessinsights.com/request_sample.php?id=562904
Top Key Players Included in This Report: Merck KGa, Roche, Nlyte, Taxotere,…
Targeted Drugs for NSCLC Market Size by 2025: QY Research
Global Targeted Drugs for NSCLC market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail…
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot:
NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit…
Global cancer immunotherapies Market 2016:Melanoma, Prostate cancer, NSCLC
Cancer Immunotherapies has brought an unprecedented change in the global cancer therapies market. Cancer immunotherapy can be defined as, the treatment that deploys the bodys immune system, by joining and boosting innate powers of the immune system to fight cancer.
Over the past few years, cancer immunotherapies have generated new waves of optimism in the global oncology market, unveiling huge untapped potential for the innovators. After years of jostling over how…
